Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share

How Big Is the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Expected to Be, and What Will Its Growth Rate Be?
The market size of the poly ADP-ribose polymerase (PARP) inhibitor has seen notable expansion in the past few years. The market is projected to rise from $8.39 billion in 2024 to $9.41 billion in 2025, accounting for a compound annual growth rate (CAGR) of 12.1%. Factors contributing to the growth seen in the historical phase include clinical studies, regulatory approvals, market rivalry, drug mixtures, and patient advocacy.

The market size for poly ADP-ribose polymerase (PARP) inhibitors is anticipated to experience a quick expansion in the approaching years. It is projected to escalate to $14.67 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.7%. Various factors such as broader indications, tailor-made medicine, biomarker enhancement, health economic factors, and surging markets contribute to the expected growth during the forecast period. Key trends anticipated during this period encapsulate precision medicine, advancing immunotherapy, targeted treatments, the application of artificial intelligence in drug discovery, and a patient-centred healthcare approach.

What Are the Primary Growth Drivers for the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The surge in ovarian cancer cases is predicted to fuel the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer, a malignant tumor found in one or both a woman's ovaries, which is part of the female reproductive system producing eggs and female hormones, is on the rise. The increase can be attributed to factors such as genetic tendencies, aging populations, environmental factors, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are utilized in treating ovarian cancer, specifically targeting DNA repair processes in patients with BRCA mutations, leading to enhanced cancer cell death. For example, data from the World Ovarian Cancer Coalition, a Canadian non-profit organization, in February 2024 suggests that the annual number of ovarian cancer-related deaths among women is expected to rise to 350,956, a nearly 70% increase from 2022. Thus, the growing incidence of ovarian cancer is stimulating the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp

Who Are the Dominant Companies Influencing Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Trends?
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

How Is the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Evolving?
Top enterprises in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on the development of generic PARP inhibitors. The intention is to provide genetically tailored treatments for cancer-affected individuals with specific gene anomalies. These inhibitors are a type of medicines that interrupt the activity of the enzyme poly ADP-ribose polymerase (PARP). To illustrate, Zydus Lifesciences Limited, a pharmaceutical firm from India, launched a PARP inhibitor named Olaparib under the IBYRA brand in March 2024. The objective was to widen the availability of progressive cancer treatment. IBYRA is developed to target distinct genetic variations observed in cancers of the breast, ovaries, prostate, and pancreas, thereby delivering a customised and efficient treatment regime. The medication is especially advantageous for patients with HRD-positive or BRACA mutations, as it helps postpone the progression of the disease.

What Are the Different Segmentations in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented -

1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report

Which Region Is at the Forefront of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report?

- Market Size Analysis: Analyze the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Poly ADP-Ribose Polymerase (PARP) Inhibitor Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.